MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2021

Nov 8, 2021

==> picture [104 x 26] intentionally omitted <==

ASX Announcement

09 November 2021

MACH 7 TECHNOLOGIES CEO TO PRESENT AT BELL POTTER HEALTHCARE CONFERENCE

Mach7 Technologies Limited ( M7T or the Company ) is pleased to announce that Mike Lampron, M7T’s CEO will be presenting the attached Presentation at the Bell Potter

th Healthcare Conference at 10:00am on Tuesday the 9 of November 2021 (AEDT). The Company looks forward to engaging with all interested parties.

Released on authority of the Board by:

Mike Lampron Chief Executive Officer

For more information, contact:

Veronique Morgan-Smith Company Secretary vmorgansmith@leydinfreyer.com.au

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative data management solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their bestof-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit Mach7t.com.

==> picture [182 x 64] intentionally omitted <==

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192 Registered Office: Level 4, 96 – 100 Albert Road, South Melbourne, VIC 3205 T: 03 9692 7222 www.mach7.com

==> picture [187 x 46] intentionally omitted <==

1 ///

==> picture [10 x 540] intentionally omitted <==

==> picture [221 x 33] intentionally omitted <==

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“ M7T ”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so. Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks,

uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

2 ///

==> picture [960 x 374] intentionally omitted <==

----- Start of picture text -----

More than 150
customers spanning
15 countries
Hospitals and healthcare
entities around the world deploy
Mach7’s solutions and
innovative technologies.
We have built a global network
of diverse customers that range
from expansive Integrated
Delivery Networks, National
----- End of picture text -----

Hospital systems around the world use Mach7 Technologies

3 ///

==> picture [384 x 41] intentionally omitted <==

==> picture [25 x 5] intentionally omitted <==

==> picture [413 x 41] intentionally omitted <==

==> picture [303 x 183] intentionally omitted <==

==> picture [767 x 159] intentionally omitted <==

----- Start of picture text -----

“I have the
“I have “I can offer
“I see how
information I
“I see how it is
integrated more services
systems are
need to support
reporting and performing” & information”
running”
high quality
KPIs”
care”
Policy Operations Business Vendors Health Care
Administrator
Provider
----- End of picture text -----

4 ///

At Mach7, we provide an Enterprise Imaging Platform, that provides:

==> picture [283 x 303] intentionally omitted <==

----- Start of picture text -----

Consolidation of all
images
At the core of this platform is a
Vendor Neutral Archive which
consolidates all images and
reports across the enterprise
into a single repository.
Removing redundant
operating expenses across an
enterprise.
----- End of picture text -----

==> picture [284 x 303] intentionally omitted <==

----- Start of picture text -----

Access all images
We then enable access to this
data to enterprise users
directly or through the
Electronic Medical Record
using our true zero footprint
viewer. This combined solution
insulates the enterprise users
from radiology departmental
technology changes or
departmental downtime
issues.
----- End of picture text -----

==> picture [283 x 303] intentionally omitted <==

----- Start of picture text -----

PACS solution
The enterprise platform can be
used as a diagnostic PACS
solution, research platform, or
AI integration platform without
impacting clinical workflow.
This is a software only solution
that leverages our customers
existing IT infrastructure to
streamline workflow and
reduce IT burden.
----- End of picture text -----

5 ///

==> picture [10 x 540] intentionally omitted <==

==> picture [499 x 38] intentionally omitted <==

==> picture [320 x 38] intentionally omitted <==

An enterprise-wide, interoperable platform for storing, retrieving and viewing all medical imaging data in one vendor neutral ecosystem. Consisting of:

• Enterprise Data Management

• Enterprise Diagnostic Viewing

• • Enterprise PACS

==> picture [307 x 520] intentionally omitted <==

6 ///

==> picture [928 x 247] intentionally omitted <==

==> picture [27 x 28] intentionally omitted <==

==> picture [140 x 33] intentionally omitted <==

==> picture [208 x 42] intentionally omitted <==

• •

• Integrated Delivery Networks Centers of Excellence

• • • International hospital Imaging Centers authorities and health systems • Telehealth service providers

• Regional and community hospital systems

• Integration platform for

• hospital systems external systems (EMR, VR,

• • Academic medical institutions Image Sharing, HIEs)

• • • Medical Research facilities Strategic partnerships

• • • Independent Provider Groups Children’s Health Centers

7 ///

==> picture [540 x 39] intentionally omitted <==

• $25.6M Sales Orders (TCV*); Highest on Record; up 95%;

• 20% of Sales Orders are SAAS; Up from 3% in FY20

• 97% Gross Margin %; Up from 87% in FY2020

• $18.4M Gross Margins; Up 12%

• $19.0M Revenue; Up 1%; (Up 13% on a constant currency basis)

• EBITDA Loss -$1.8M; (FY20 Profit $3.3M)

• *Total Contract Value (TCV) means software license fees,

• professional service fees and annual support (or annual subscription) over the life of the contract.

==> picture [309 x 488] intentionally omitted <==

8 ///

==> picture [188 x 52] intentionally omitted <==

----- Start of picture text -----

M&A
----- End of picture text -----

==> picture [105 x 51] intentionally omitted <==

----- Start of picture text -----

Awards
----- End of picture text -----

==> picture [102 x 102] intentionally omitted <==

==> picture [195 x 52] intentionally omitted <==

----- Start of picture text -----

Sales Up 95%
----- End of picture text -----

==> picture [114 x 115] intentionally omitted <==

==> picture [155 x 51] intentionally omitted <==

----- Start of picture text -----

ARR Up 80%
----- End of picture text -----

==> picture [299 x 405] intentionally omitted <==

----- Start of picture text -----

New Talent
Steve Parkes, CFO
David Madaffri, VP Sales
Lisa Thompson, VP Services
CIO Review
----- End of picture text -----

9 ///

• Sales orders $16.2M (TCV); up 368% on last quarter (Q4’21 $4.4M)

• Major expansion contract wins secured from Trinity Health and Advocate Aurora Healthcare

• Contracted annual recurring revenue (CARR) $16.8M; up 6% (or 24% annualized) (Q4’21 $15.8M)

• Cash on hand $17.2M; (30 June 2021 $18.4M)

• *Total Contract Value (TCV) means software license fees, professional service fees and annual support

(or annual subscription) over the life of the contract.

10 ///

==> picture [188 x 52] intentionally omitted <==

----- Start of picture text -----

Financial
----- End of picture text -----

==> picture [195 x 52] intentionally omitted <==

----- Start of picture text -----

Product
----- End of picture text -----

==> picture [195 x 52] intentionally omitted <==

----- Start of picture text -----

Sales & Marketing
----- End of picture text -----

• •

==> picture [206 x 405] intentionally omitted <==

----- Start of picture text -----

Industry
Focused on Enterprise
Data Management, the
backbone of an
Enterprise Strategy
Focused on providing
the best enterprise
zero foot-print viewer
in the industry
Enterprise Imaging is
growing by segment in
the industry every year,
----- End of picture text -----

11 ///

Organic Growth strategy

• Market transition from Radiology PACS focus to enterprise informatics focus. Mach7 VNA and Enterprise Viewer ideally suited for paradigm shift.

• Opportunity growth by 3[rd] party resellers of Mach7 solutions as they also focus on evolving enterprise informatics paradigm.

• Recruitment of highly skilled sales team has resulted in increased market visibility and strong funnel growth.

• Portfolio cross selling opportunities increasing as a result of completed

integration of Client Outlook.

• Additional growth of recurring revenue from customers who reach “go live” on the

Platform

Acquisitive Growth Strategy

• If we find opportunity that can fill product gaps and/or provide great value to our customers, we will evaluate that opportunity

• We are 100% committed to being cashflow positive into the future

• • Timing will be important as we feel undervalued in the market at present

==> picture [282 x 359] intentionally omitted <==

----- Start of picture text -----

We are opportunistic in
regards to acquisition and
100% committed to
remaining cashflow
positive on an annual
basis
----- End of picture text -----

12 ///